Extension of NetraMark’s NetraPharma Collaboration with Juvenescence

NetraMark Corp., a next generation AI + health data technology company and Juvenescence Limited, a life sciences company utilizing expert drug developers and artificial intelligence experts to create therapeutics and technologies to treat diseases of aging and to increase human longevity, are pleased to announce the extension of their collaboration agreement to include drug repurposing and drug discovery.

Dr. Joseph Geraci, CEO of NetraMark, said: “After years of development and validation by the NetraMark tech team, the NetraAI machine learning suite is providing us with valuable insights into aging. The result is a very exciting collaboration with Juvenescence, one of the premier biotech companies focusing on modifying aging. Their efforts provide a perfect application of our solution which allows us, unlike other AI companies, to extract valuable and clear insights from limited data sets, to provide novel therapeutics for complex disorders like aging.”

Dr. Gregory Bailey, CEO of Juvenescence, said: “NetraMark Corp. and Juvenescence Limited are pleased to announce the extension of their business relationship. We are very excited to extend the relationship with NetraMark beyond drug resurrection to also include drug repurposing and drug discovery to find novel drugs and drug targets relating to longevity. We see this as a novel collaboration to combine NetraMark’s diverse and unique machine learning platform with Juvenescence, as we are positioned as one of the leading drug development companies in the rapidly expanding sector focused on developing therapies to modify aging.”


NetraMark is a Toronto-based tech venture with dedicated solutions for pharmaceutical and biotech companies. NetraMark’s AI platform was designed to extract insights from complex patient populations for patient stratification, placebo response prediction, drug repurposing, and precision multi-target identification. The AI paradigm was discovered by CEO Dr. Joseph Geraci, a mathematician, medical scientist, and quantum machine learning specialist who began commercializing the idea in 2017 with the help of COO Richard Brooks, a business lawyer and serial entrepreneur who has supported Canadian start-ups for more than 20 years. For more information, please visit netramark.com


Juvenescence Limited is a life sciences company developing therapies to modify aging and increase healthy human longevity. It was founded by Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan. The Juvenescence team are highly experienced drug developers, entrepreneurs and investors with a significant history of success in the life sciences sector. Juvenescence will create, partner with or invest in new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures to develop therapeutics for longevity. Juvenescence believes that recent advances in science have greatly improved our understanding of the biology of aging and seeks to develop therapeutics with the possibility of slowing, halting or potentially reversing elements of aging.

Link to the Press Release found here.